The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 20, 2019

Filed:

Apr. 11, 2014
Applicants:

Dennis M. Brown, Menlo Park, CA (US);

Ian Nisbet, Victoria, AU;

Inventors:

Dennis M. Brown, Menlo Park, CA (US);

Ian Nisbet, Victoria, AU;

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/404 (2006.01); A61K 45/06 (2006.01); C07K 16/40 (2006.01); C12N 15/113 (2010.01); A61K 31/7056 (2006.01); A61K 39/395 (2006.01); C07D 209/34 (2006.01);
U.S. Cl.
CPC ...
A61K 31/404 (2013.01); A61K 31/7056 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07D 209/34 (2013.01); C07K 16/40 (2013.01); C12N 15/1137 (2013.01); C12N 2310/141 (2013.01); C12N 2320/31 (2013.01);
Abstract

The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutically active agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to therapeutically active agents selected from the group consisting of: (i) indirubin; (ii) an analog of indirubin; (iii) a derivative of indirubin or of an analog of indirubin; and (iv) a pharmaceutical composition comprising indirubin, an analog of indirubin, or a derivative of indirubin or of an analog of indirubin, especially meisoindigo. In particular, the therapeutically active agents selected from the group consisting of: (i) indirubin; (ii) an analog of indirubin; (iii) a derivative of indirubin or of an analog of indirubin; and (iv) a pharmaceutical composition comprising indirubin, an analog of indirubin, or a derivative of indirubin or of an analog of indirubin, especially meisoindigo, are effective Nek9 inhibitors. The active agent, such as meisoindigo, can act as a Nek9 inhibitor. The active agent can be used together with Nek9 inhibitors or agents that inhibit the expression of Nek9.


Find Patent Forward Citations

Loading…